Glypvilo (Vildagliptin)

Glypvilo is a prescription medication that contains the active ingredient vildagliptin, a dipeptidyl peptidase‑4 (DPP‑4) inhibitor, supplied as oral tablets (strength not specified) for use in the European Union. It belongs to the antidiabetic therapeutic class and works by enhancing the body’s natural incretin response to improve blood glucose control in adults with type 2 diabetes mellitus.

Glypvilo is indicated for the management of type 2 diabetes mellitus in adults.

- Improves glycemic control when used as part of a comprehensive diabetes management plan that includes diet and exercise. - Can be prescribed as monotherapy in patients who have not achieved target glucose levels with lifestyle measures alone. - Often combined with other oral antidiabetic agents such as metformin, sulfonylureas, or thiazolidinediones to enhance overall efficacy. - May be added to insulin therapy for patients requiring additional glucose lowering. - Considered for use in patients with mild to moderate renal impairment, with dosing adjustments as recommended in the prescribing information.

The safety profile of Glypvilo includes both common and rare adverse events that have been reported in clinical use.

Common: - Nausea or upset stomach. - Headache. - Dizziness or light‑headedness. - Upper respiratory tract infection symptoms. - Mild hypoglycemia, especially when combined with insulin or sulfonylureas.

Serious: - Acute pancreatitis. - Severe allergic reactions such as angioedema or anaphylaxis. - Hepatic dysfunction indicated by elevated liver enzymes. - Bullous skin disorders (e.g., Stevens‑Johnson syndrome). - Severe hypoglycemia requiring medical intervention.

When prescribing Glypvilo, clinicians should consider several precautionary measures to ensure safe use.

- Assess renal function before initiation and monitor periodically, adjusting dose as needed. - Evaluate hepatic function, especially in patients with known liver disease. - Use caution in elderly patients who may be more susceptible to hypoglycemia. - Avoid use during pregnancy and lactation unless the potential benefit justifies the risk, as safety data are limited. - Monitor for signs of pancreatitis, such as persistent abdominal pain. - Be aware of a history of severe allergic reactions to DPP‑4 inhibitors.

Glypvilo can interact with other medications, influencing its efficacy and safety.

Avoid: - Concomitant use with other DPP‑4 inhibitors or GLP‑1 receptor agonists due to overlapping mechanisms. - Unadjusted combination with insulin or sulfonylureas, which may increase the risk of hypoglycemia.

Use with caution: - In patients receiving diuretics or antihypertensive agents, as changes in fluid balance may affect glucose control. - When co‑administered with drugs that affect renal clearance, such as certain antibiotics. - With medications that have hepatic metabolism, to monitor for potential liver enzyme elevations. - In combination with warfarin or other anticoagulants, monitor coagulation parameters.